Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera

Vaccine

Volumn 29, Issue 47, 2011, Pages 8585-8590

  Draper, Eve ^a   Bissett, Sara L ^a   Howell Jones, Rebecca ^a   Edwards, Debbie ^b   Munslow, Graham ^b   Soldan, Kate ^a   Beddows, Simon ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b BOLTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antibody; Human papillomavirus; Vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; WART VIRUS VACCINE;

ADOLESCENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; IMMUNIZATION; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SPECIES DIFFERENCE; UTERINE CERVIX CANCER; VIRUS NEUTRALIZATION; VIRUS STRAIN; WART VIRUS;

ADOLESCENT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; CROSS REACTIONS; FEMALE; GREAT BRITAIN; HUMANS; INFANT; MALE; NEUTRALIZATION TESTS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES;

EID: 82455175338     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.021     Document Type: Article

References (37)

1. Schiller J.T., Lowy D.R. Vaccines to prevent infections by oncoviruses. Annu Rev Microbiol 2010, 64:23-41.
2. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348(6):518-527.
3. Li N., Franceschi S., Howell-Jones R., Snijders P.J., Clifford G.M. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2010, 128(4):927-935.
4. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(9686):301-314.
5. Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., Perez G., et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009, 2(10):868-878.
6. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995, 92(25):11553-11557.
7. Breitburd F., Kirnbauer R., Hubbert N.L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995, 69(6):3959-3963.
8. Frazer I.H. Measuring serum antibody to human papillomavirus following infection or vaccination. Gynecol Oncol 2010, 118(1 Suppl.):S8-S11.
9. Stanley M. Potential mechanisms for HPV vaccine-induced long-term protection. Gynecol Oncol 2010, 118(1 Suppl.):S2-S7.
10. Schiller J.T., Lowy D.R. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 2009, 200(2):166-171.
11. Cohen J. Public health. High hopes and dilemmas for a cervical cancer vaccine. Science 2005, 308(5722):618-621.
12. Kemp T.J., Garcia-Pineres A., Falk R.T., Poncelet S., Dessy F., Giannini S.L., et al. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 2008, 26(29-30):3608-3616.
13. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., et al. A review of human carcinogens. Part B. Biological agents. Lancet Oncol 2009, 10(4):321-322.
14. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., zur Hausen H. Classification of papillomaviruses. Virology 2004, 324(1):17-27.
15. Bernard H.U., Burk R.D., Chen Z., van Doorslaer K., Hausen H., de Villiers E.M. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010, 401(1):70-79.
16. Wheeler C.M., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Perez G., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009, 199(7):936-944.
17. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199(7):926-935.
18. Ochi H., Kondo K., Matsumoto K., Oki A., Yasugi T., Furuta R., et al. Neutralizing antibodies against human papillomavirus types 16, 18, 31, 52, and 58 in serum samples from women in Japan with low-grade cervical intraepithelial neoplasia. Clin Vaccine Immunol 2008, 15(10):1536-1540.
19. Jagu S., Karanam B., Gambhira R., Chivukula S.V., Chaganti R.J., Lowy D.R., et al. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 2009, 101(11):782-792.
20. Kemp T.J., Hildesheim A., Safaeian M., Dauner J.G., Pan Y., Porras C., et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 2011, 29(11):2011-2014.
21. Smith J.F., Brownlow M., Brown M., Kowalski R., Esser M.T., Ruiz W., et al. Antibodies from women immunized with gardasil ((R)) cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007, 3(4):109-116.
22. Krajden M., Cook D., Yu A., Chow R., Mei W., McNeil S., et al. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clin Vaccine Immunol 2011, 18(3):418-423.
23. UK Department of Health Human papillomavirus (HPV). Immunisation against infectious disease - 'The Green Book' 2011, The Stationery Office. D. Salisbury, M. Ramsay, K. Noakes (Eds.).
24. Buck C.B., Thompson C.D. Production of papillomavirus-based gene transfer vectors. Curr Protoc Cell Biol 2007, chapter 26: unit 26 1.
25. Pastrana D.V., Buck C.B., Pang Y.Y., Thompson C.D., Castle P.E., FitzGerald P.C., et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004, 321(2):205-216.
26. Buck C.B., Pastrana D.V., Lowy D.R., Schiller J.T. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med 2005, 119:445-462.
27. Buck C.B., Thompson C.D., Roberts J.N., Muller M., Lowy D.R., Schiller J.T. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog 2006, 2(7):e69.
28. Selinka H.C., Giroglou T., Nowak T., Christensen N.D., Sapp M. Further evidence that papillomavirus capsids exist in two distinct conformations. J Virol 2003, 77(24):12961-12967.
29. Johnson K.M., Kines R.C., Roberts J.N., Lowy D.R., Schiller J.T., Day P.M. Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol 2009, 83(5):2067-2074.
30. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367(9518):1247-1255.
31. Petaja T., Keranen H., Karppa T., Kawa A., Lantela S., Siitari-Mattila M., et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 2009, 44(1):33-40.
32. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006, 24(27-28):5571-5583.
33. Herrero R., Hildesheim A., Rodriguez A.C., Wacholder S., Bratti C., Solomon D., et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 2008, 26(37):4795-4808.
34. Jit M., Vyse A., Borrow R., Pebody R., Soldan K., Miller E. Prevalence of human papillomavirus antibodies in young females in England. Br J Cancer 2007, 97:989-991.
35. De Carvalho N., Teixeira J., Roteli-Martins C.M., Naud P., De Borba P., Zahaf T., et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010, 28(38):6247-6255.
36. Plotkin S.A. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008, 47(3):401-409.
37. Plotkin S.A. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010, 17(7):1055-1065.